Lyell Immunopharma Analyst Ratings
Lyell Immunopharma Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/11/2022 | — | Goldman Sachs | Downgrades | Buy → Neutral | |
10/17/2022 | 171.49% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
05/24/2022 | 171.49% | Goldman Sachs | $21 → $12 | Maintains | Buy |
03/31/2022 | 375.11% | Goldman Sachs | $31 → $21 | Maintains | Buy |
01/06/2022 | 352.49% | Morgan Stanley | $25 → $20 | Maintains | Overweight |
07/12/2021 | 465.61% | Morgan Stanley | → $25 | Initiates Coverage On | → Overweight |
07/12/2021 | 465.61% | B of A Securities | → $25 | Initiates Coverage On | → Buy |
07/12/2021 | 397.74% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
07/12/2021 | 578.73% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
---|---|---|---|---|---|
11/11/2022 | — | 高盛 | 降級 | 購買 → 中性 | |
2022 年 10 月 17 日 | 171.49% | HC 溫賴特 & 有限公司. | → 十二美元 | 啟動覆蓋範圍 | → 購買 |
2022 年 5 月 24 日 | 171.49% | 高盛 | 二十一美元 → 十二美元 | 維護 | 購買 |
03/31/2022 | 375.11% | 高盛 | 三十一美元 → 二十一美元 | 維護 | 購買 |
2022 年 6 月 1 日 | 352.49% | 摩根士丹利 | 25 美元 → 20 美元 | 維護 | 超重 |
2021 年 12 月 7 日 | 465.61% | 摩根士丹利 | → 25 美元 | 啟動覆蓋範圍 | → 超重 |
2021 年 12 月 7 日 | 465.61% | A 之 B 證券 | → 25 美元 | 啟動覆蓋範圍 | → 購買 |
2021 年 12 月 7 日 | 397.74% | 摩根大通 | → 二十二美元 | 啟動覆蓋範圍 | → 超重 |
2021 年 12 月 7 日 | 578.73% | 高盛 | → 30 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for Lyell Immunopharma (LYEL)?
萊爾免疫藥(LYEL)的目標價格是多少?
The latest price target for Lyell Immunopharma (NASDAQ: LYEL) was reported by Goldman Sachs on November 11, 2022. The analyst firm set a price target for $0.00 expecting LYEL to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
高盛於 2022 年 11 月 11 日報導了萊爾免疫藥(納斯達克代碼:LYEL)的最新價格目標。該分析師公司將價格目標設定為 0.00 美元,預計 LYEL 將在 12 個月內跌至 12 個月內(下行可能為 -100.00%)。5 家分析師公司在去年報告了評級。
What is the most recent analyst rating for Lyell Immunopharma (LYEL)?
萊爾免疫藥(LYEL)的最新分析師評級為何?
The latest analyst rating for Lyell Immunopharma (NASDAQ: LYEL) was provided by Goldman Sachs, and Lyell Immunopharma downgraded their neutral rating.
萊爾免疫藥物(納斯達克股票代碼:LYEL)的最新分析師評級由高盛提供,萊爾免疫藥物降級中性評級。
When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?
Lyell 免疫藥(LYEL)的下一個分析師評級何時會發布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on November 11, 2022 so you should expect the next rating to be made available sometime around November 11, 2023.
分析師在進行了廣泛的研究後抵達股票評級,其中包括通過公共財務報表,與 Lyell Immunopharma 的高管和客戶交談以及聽取盈利電話會議。大多數分析師每三個月這樣做一次,因此您應該每年每家公司獲得 4 個評級。萊爾免疫藥的最後評級於 2022 年 11 月 11 日提交,因此您應該期望下一個評分將在 2023 年 11 月 11 日左右的某個時間提供。
Is the Analyst Rating Lyell Immunopharma (LYEL) correct?
分析師評級萊爾免疫藥(LYEL)是否正確?
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a downgraded with a price target of $0.00 to $0.00. The current price Lyell Immunopharma (LYEL) is trading at is $4.42, which is out of the analyst's predicted range.
儘管評級是主觀的並且會發生變化,但最新的萊爾免疫藥(LYEL)評級降級,目標價格為 0.00 美元至 0.00 美元。目前的價格萊爾免疫藥(LYEL)的交易價格為 4.42 美元,超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。